{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:32:28Z","timestamp":1780338748584,"version":"3.54.1"},"reference-count":87,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002649","name":"Yeungnam University","doi-asserted-by":"publisher","award":["2018 Yeungnam University Research Grant"],"award-info":[{"award-number":["2018 Yeungnam University Research Grant"]}],"id":[{"id":"10.13039\/501100002649","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Basic Science Research Program through the National Research Foundation of Korea (NRF) founded by the Ministry of Science, ICT and Future Planning","award":["2017R1C1B5017085"],"award-info":[{"award-number":["2017R1C1B5017085"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0234818","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T13:21:43Z","timestamp":1594732903000},"page":"e0234818","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-6827","authenticated-orcid":true,"given":"Hye Duck","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"key":"pone.0234818.ref001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/oxfordjournals.bmb.a072464","article-title":"Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers","volume":"47","author":"WJ Gullick","year":"1991","journal-title":"Br Med Bull"},{"key":"pone.0234818.ref002","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"JG Paez","year":"2004","journal-title":"Science"},{"key":"pone.0234818.ref003","unstructured":"Non-small cell lung cancer. NCCN Clinical practice guidelines in oncology (NCCN guidelines). 2019."},{"key":"pone.0234818.ref004","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/annonc\/mdr125","article-title":"Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy","volume":"23","author":"B Coudert","year":"2012","journal-title":"Ann Oncol"},{"key":"pone.0234818.ref005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"FA Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"pone.0234818.ref006","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/IOP.0b013e31802d97f0","article-title":"Newly recognized ocular side effects of erlotinib","volume":"23","author":"AB Methvin","year":"2007","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"pone.0234818.ref007","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1200\/JCO.2015.63.4154","article-title":"Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L","volume":"34","author":"Y Urata","year":"2016","journal-title":"J Clin Oncol"},{"key":"pone.0234818.ref008","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s10549-017-4460-9","article-title":"Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis","volume":"166","author":"HD Choi","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0234818.ref009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"7","author":"AR Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"pone.0234818.ref010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"WG Cochran","year":"1954","journal-title":"Biometrics"},{"key":"pone.0234818.ref011","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective sties of diseases","volume":"22","author":"N Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"pone.0234818.ref012","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"pone.0234818.ref013","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"CB Begg","year":"1994","journal-title":"Biometircs"},{"key":"pone.0234818.ref014","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ"},{"key":"pone.0234818.ref015","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analysis: The PRISMA Statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"key":"pone.0234818.ref016","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/JTO.0b013e31818026f6","article-title":"Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study","volume":"3","author":"O Arrieta","year":"2008","journal-title":"J Thorac Oncol"},{"key":"pone.0234818.ref017","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1158\/1078-0432.CCR-07-5186","article-title":"A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy","volume":"14","author":"E Felip","year":"2008","journal-title":"Clin Cancer Res"},{"key":"pone.0234818.ref018","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/JTO.0b013e318183aa1f","article-title":"Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2","volume":"3","author":"PJ Hesketh","year":"2008","journal-title":"J Thorac Oncol"},{"key":"pone.0234818.ref019","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e31818d6702","article-title":"Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study","volume":"3","author":"K Kubota","year":"2008","journal-title":"J Thorac Oncol"},{"key":"pone.0234818.ref020","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/annonc\/mdn423","article-title":"Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment","volume":"19","author":"DH Lee","year":"2008","journal-title":"Ann Oncol"},{"key":"pone.0234818.ref021","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2007.13.2720","article-title":"Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2","volume":"26","author":"R Lilenbaum","year":"2008","journal-title":"J Clin Oncol"},{"key":"pone.0234818.ref022","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/JTO.0b013e3181943bb9","article-title":"A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer","volume":"4","author":"W Akerley","year":"2009","journal-title":"J Thorac Oncol"},{"key":"pone.0234818.ref023","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/JTO.0b013e3181f1c7b0","article-title":"Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study","volume":"5","author":"M Reck","year":"2010","journal-title":"J Thorac Oncol"},{"key":"pone.0234818.ref024","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11523-010-0163-4","article-title":"Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial","volume":"5","author":"D Rossi","year":"2010","journal-title":"Target Oncol"},{"key":"pone.0234818.ref025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3892\/ol_00000059","article-title":"Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study","volume":"1","author":"GP Stathopoulos","year":"2010","journal-title":"Oncol Lett"},{"key":"pone.0234818.ref026","first-page":"557","article-title":"Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer","volume":"30","author":"T Takahashi","year":"2010","journal-title":"Anticancer Res"},{"key":"pone.0234818.ref027","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/JTO.0b013e3181c20063","article-title":"A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705","volume":"5","author":"H Yoshioka","year":"2010","journal-title":"J Thorac Oncol"},{"key":"pone.0234818.ref028","first-page":"3457","article-title":"Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study","volume":"31","author":"DR Choi","year":"2011","journal-title":"Anticancer Res"},{"key":"pone.0234818.ref029","first-page":"35","article-title":"Phase II study of erlotinib for chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets","volume":"6","author":"DH Lee","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"pone.0234818.ref030","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/jjco\/hyr079","article-title":"Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations","volume":"41","author":"S Matsuura","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"pone.0234818.ref031","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/bjc.2011.332","article-title":"Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer","volume":"105","author":"AC Mita","year":"2011","journal-title":"Br J Cancer"},{"key":"pone.0234818.ref032","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","article-title":"Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer","volume":"29","author":"RB Natale","year":"2011","journal-title":"J Clin Oncol"},{"key":"pone.0234818.ref033","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/JCO.2011.36.6799","article-title":"Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer","volume":"29","author":"SS Ramalingam","year":"2011","journal-title":"J Clin Oncol"},{"key":"pone.0234818.ref034","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.2010.34.0570","article-title":"Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer","volume":"29","author":"LV Sequist","year":"2011","journal-title":"J Clin Oncol"},{"key":"pone.0234818.ref035","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"C Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"pone.0234818.ref036","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(11)70385-0","article-title":"Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study","volume":"13","author":"T Ciuleanu","year":"2012","journal-title":"Lancet Oncol"},{"key":"pone.0234818.ref037","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00280-012-1831-0","article-title":"A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer","volume":"69","author":"T Kobayashi","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"pone.0234818.ref038","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1470-2045(12)70412-6","article-title":"First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"SM Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"pone.0234818.ref039","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1200\/JCO.2011.39.9782","article-title":"Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer","volume":"30","author":"M P\u00e9rol","year":"2012","journal-title":"J Clin Oncol"},{"key":"pone.0234818.ref040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"R Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"pone.0234818.ref041","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1200\/JCO.2011.39.2993","article-title":"Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial","volume":"30","author":"GV Scagliotti","year":"2012","journal-title":"J Clin Oncol"},{"key":"pone.0234818.ref042","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.2011.39.4882","article-title":"Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer","volume":"30","author":"EE Schaake","year":"2012","journal-title":"J Clin Oncol"},{"key":"pone.0234818.ref043","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.2011.38.9411","article-title":"Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy","volume":"30","author":"SE Witta","year":"2012","journal-title":"J Clin Oncol"},{"key":"pone.0234818.ref044","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.lungcan.2012.03.012","article-title":"Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study","volume":"77","author":"YL Wu","year":"2012","journal-title":"Lung Cancer"},{"key":"pone.0234818.ref045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2013.07.003","article-title":"A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)","volume":"82","author":"K Goto","year":"2013","journal-title":"Lung Cancer"},{"key":"pone.0234818.ref046","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/annonc\/mdt212","article-title":"A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)","volume":"24","author":"HJ Groen","year":"2013","journal-title":"Ann Oncol"},{"key":"pone.0234818.ref047","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/annonc\/mds529","article-title":"Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)","volume":"24","author":"YL Wu","year":"2013","journal-title":"Ann Oncol"},{"key":"pone.0234818.ref048","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jjco\/hyt056","article-title":"Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803)","volume":"43","author":"K Yamada","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"pone.0234818.ref049","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ejca.2013.10.006","article-title":"Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)","volume":"50","author":"JR Brahmer","year":"2014","journal-title":"Eur J Cancer"},{"key":"pone.0234818.ref050","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/cas.12550","article-title":"Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer","volume":"105","author":"A Gemma","year":"2014","journal-title":"Cancer Sci"},{"key":"pone.0234818.ref051","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000082","article-title":"A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer","volume":"9","author":"BJ Gitlitz","year":"2014","journal-title":"J Thorac Oncol"},{"key":"pone.0234818.ref052","first-page":"1975","article-title":"Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer","volume":"34","author":"A Horiike","year":"2014","journal-title":"Anticancer Res"},{"key":"pone.0234818.ref053","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2013.52.4694","article-title":"Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)","volume":"32","author":"T Kawaguchi","year":"2014","journal-title":"J Clin Oncol"},{"key":"pone.0234818.ref054","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.lungcan.2014.08.019","article-title":"A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never\/light smoking history: re-evaluation of EGFR gene status (NEJ006\/TCOG0903)","volume":"86","author":"Y Matsumoto","year":"2014","journal-title":"Lung Cancer"},{"key":"pone.0234818.ref055","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3892\/mco.2014.354","article-title":"Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System","volume":"2","author":"M Morise","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"pone.0234818.ref056","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"T Seto","year":"2014","journal-title":"Lancet Oncol"},{"key":"pone.0234818.ref057","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.lungcan.2014.09.015","article-title":"Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer","volume":"86","author":"H Yoshioka","year":"2014","journal-title":"Lung Cancer"},{"key":"pone.0234818.ref058","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial","volume":"33","author":"K Kelly","year":"2015","journal-title":"J Clin Oncol"},{"key":"pone.0234818.ref059","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13104-015-1214-9","article-title":"A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer","volume":"8","author":"H Minemura","year":"2015","journal-title":"BMC Res Notes"},{"key":"pone.0234818.ref060","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/cncr.29480","article-title":"Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer","volume":"121","author":"KL Reckamp","year":"2015","journal-title":"Cancer"},{"key":"pone.0234818.ref061","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analysis from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"YL Wu","year":"2015","journal-title":"Ann Oncol"},{"key":"pone.0234818.ref062","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ejca.2015.06.120","article-title":"A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911","volume":"51","author":"K Yamada","year":"2015","journal-title":"Eur J Cancer"},{"key":"pone.0234818.ref063","doi-asserted-by":"crossref","first-page":"e0147599","DOI":"10.1371\/journal.pone.0147599","article-title":"Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)","volume":"11","author":"J De Greve","year":"2016","journal-title":"PLoS One"},{"key":"pone.0234818.ref064","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jtho.2015.11.003","article-title":"SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin\/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay","volume":"11","author":"PN Lara","year":"2016","journal-title":"J Thorac Oncol"},{"key":"pone.0234818.ref065","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S1470-2045(16)30561-7","article-title":"Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial","volume":"17","author":"JW Neal","year":"2016","journal-title":"Lancet Oncol"},{"key":"pone.0234818.ref066","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2015.66.0084","article-title":"The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer","volume":"34","author":"V Papadimitrakopoulou","year":"2016","journal-title":"J Clin Oncol"},{"key":"pone.0234818.ref067","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamaoncol.2015.4921","article-title":"First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study","volume":"2","author":"K Park","year":"2016","journal-title":"JAMA Oncol"},{"key":"pone.0234818.ref068","first-page":"2881","article-title":"Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802)","volume":"36","author":"K Yamada","year":"2016","journal-title":"Anticancer Res"},{"key":"pone.0234818.ref069","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bjc.2017.226","article-title":"Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer","volume":"117","author":"TE Ciuleanu","year":"2017","journal-title":"Br J Cancer"},{"key":"pone.0234818.ref070","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00280-017-3432-4","article-title":"A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)","volume":"80","author":"Y Ikezawa","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"pone.0234818.ref071","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cllc.2016.07.007","article-title":"Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations","volume":"18","author":"NB Leighl","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"pone.0234818.ref072","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3892\/mco.2017.1154","article-title":"Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)","volume":"6","author":"M Miyawaki","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"pone.0234818.ref073","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/bjc.2016.456","article-title":"A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations","volume":"116","author":"JJ Yang","year":"2017","journal-title":"Br J Cancer"},{"key":"pone.0234818.ref074","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"M Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"key":"pone.0234818.ref075","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/cncr.22088","article-title":"A phase I\/II study of weekly high dose erlotinib in previously treated patients with non-small cell cancer","volume":"107","author":"DT Milton","year":"2006","journal-title":"Cancer"},{"key":"pone.0234818.ref076","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00003226-200101000-00016","article-title":"Expression of the receptor tyrosine kinases, epidermal growth factor receptor, erbb2, and erbb3, in human ocular surface epithelia","volume":"20","author":"Z Liu","year":"2001","journal-title":"Cornea"},{"key":"pone.0234818.ref077","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1242\/jcs.106.1.145","article-title":"Regional variation in distribution of EGF receptor in developing and adult corneal epithelium","volume":"106","author":"JD Zieske","year":"1993","journal-title":"J Cell Sci"},{"key":"pone.0234818.ref078","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1006\/exer.2000.0979","article-title":"The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis","volume":"72","author":"Y Nakamura","year":"2001","journal-title":"Exp Eye Res"},{"key":"pone.0234818.ref079","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/ICO.0b013e318064584a","article-title":"Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors","volume":"26","author":"G Zhang","year":"2007","journal-title":"Cornea"},{"key":"pone.0234818.ref080","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00520-012-1645-y","article-title":"Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review","volume":"21","author":"DS Borkar","year":"2013","journal-title":"Support Care Cancer"},{"key":"pone.0234818.ref081","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14740338.2011.540799","article-title":"Reviewing the safety of erlotinib in non-small cell lung cancer","volume":"10","author":"M Reck","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0234818.ref082","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1186\/s12885-018-4891-7","article-title":"Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study","volume":"18","author":"MK Kim","year":"2018","journal-title":"BMC Cancer"},{"key":"pone.0234818.ref083","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/JTO.0b013e3181d32287","article-title":"Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis","volume":"5","author":"Y Togashi","year":"2010","journal-title":"J Thorac Oncol"},{"key":"pone.0234818.ref084","doi-asserted-by":"crossref","first-page":"e54738","DOI":"10.1371\/journal.pone.0054738","article-title":"Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats","volume":"8","author":"RN Bou Matar","year":"2013","journal-title":"PLoS One"},{"key":"pone.0234818.ref085","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfx264","article-title":"Erlotinib attenuates the progression of chronic kidney disease in rats with remnant kidney","volume":"33","author":"Y Yamamoto","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"pone.0234818.ref086","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.tem.2015.09.003","article-title":"Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm?","volume":"26","author":"A Fountas","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"pone.0234818.ref087","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2337\/db17-1513","article-title":"Inhibition of epidermal growth factor receptor activation is associated with improved diabetic nephropathy and insulin resistance in type 2 diabetes","volume":"67","author":"Z Li","year":"2018","journal-title":"Diabetes"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T15:36:09Z","timestamp":1667403369000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234818"}},"subtitle":[],"editor":[{"given":"Giandomenico","family":"Roviello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":87,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0234818","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.11555\/v1","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,14]]}}}